email article
A novel protein-based multitarget fecal immunochemical test (mFIT) for colorectal cancer (CRC) screening was superior to conventional FIT in detecting advanced neoplasia, particularly advanced adenomas, Dutch researchers found.
If performed on patients every 2 years, mFIT would reduce CRC incidence and death by 12% and 8%, respectively, assuming a 73% adherence rate, compared with conventional FIT screening, reported Meike de Wit, PhD, of The Netherlands Cancer Institute in Amsterdam, and colleagues.
These rates would increase to 17% and 11%, respectively, with perfect adherence, they noted in
Furthermore, the authors determined that mFIT, when applied to a validated screening model, was cost effective up to at least $84 per test.
Lung cancer
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Recovery after prolonged ICU treatment in patients with COVID-19
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Odds of COVID Death Rose When Hospital Cases Surged
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.